Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ADME and pharmacokinetics study of [14C]LNP023 in healthy volunteers
NL-OMON48316Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Iptacopan in autoimmune disease, sponsored by Novartis. Primary endpoints: Plasma pharmacokinetics of LNP023 and key metabolites, Total radioactivity pharmacokinetics in blood and plasma and 1 more. Started Jun 2019; status: active, not recruiting.
02
Drugs
Iptacopan
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON48316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48316.